REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Replimune Group, Inc.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$11.05+0.19 (+1.75%)
Close on Oct 19, 2026
- Market cap
- $1.07B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$6.55 (+145.6%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $1.07B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 10.13
- Dividend yield
- –
- Free cash flow yield
- -26.21%
Fundamentals
- Net income
- -$297.01M
- EPS, diluted
- -$3.16
- Free cash flow
- -$280.55M
- Book value per share
- $1.09
- Diluted shares
- 97M
Eleven years at a glance
Fiscal years 2016 to 2026 and trailing twelve months, USD
Operating income
-$297.74M
Net income
-$297.01M
EPS, diluted
-$3.16
Free cash flow
-$280.55M
Reported periodTrailing twelve months